2025-05-28 14:17:37

BioMaxima will produce MIC tests based on a biomedical composite material from Arctic Paper.

Press Release
Lublin, 28.05.2025 r.
Arctic Paper S.A. and BioMaxima S.A. announce that on 28 May 2025, a cooperation agreement was concluded between Arctic Paper S.A., based in Kostrzyn, and BioMaxima S.A., based in Lublin. Under this agreement, Arctic Paper S.A. will produce, exclusively for BioMaxima S.A., a biomedical composite used in the production of test strips for detecting the minimum inhibitory concentration (MIC) of microbial growth.
The test strips, developed as a layered composite, in which the carrier layer containing the inhibitory substance consists of a fibrous composite, have been designed and are the subject of a patent application filed by BioMaxima S.A. The implementation of the composite material for the carrier layer into mass production was carried out by Arctic Paper Kostrzyn S.A.
According to Łukasz Urban, CEO of BioMaxima S.A., the cooperation with Arctic Paper S.A. ensures scalable deliveries of composite material with consistent quality parameters, which is crucial for the production of MIC tests by BioMaxima S.A., a medical device:
"Our innovative MIC test production technology, based on a biomedical composite that leverages the advantages of synthetic polymer fibres, imposes high quality requirements on the supplier of this material. Thanks to our cooperation with Arctic Paper Kostrzyn S.A.'s R&D department and the creative use of their extensive experience in papermaking technology, we have secured a supplier capable of delivering the necessary and consistent material parameters for serial production. MIC tests for determining the minimum inhibitory concentration of an antibiotic are considered by physicians and microbiologists as one of the key tools in selecting targeted antibiotic therapy, which increases the chance of therapeutic success. Targeted antibiotic therapy based on MIC determination shortens treatment time, reduces complications, and enables rational antibiotic stewardship, which helps reduce the risk of microbial resistance and preserves antibiotic effectiveness for future generations. Thanks to the collaboration with Arctic Paper S.A., BioMaxima S.A. can provide this medical device to a broad base of recipients worldwide. This is our next step in developing fiber technology beyond traditional applications.”
Michał Jarczyński, CEO of Arctic Paper S.A., added:
"Arctic Paper S.A. is entering new areas of production, utilizing our experience and expertise in fiber technology. The ability to produce a biomedical composite that serves as a carrier of active substances in tests used by diagnosticians demonstrates the broad range of applications for our mastered technologies and the innovativeness of our R&D department. BioMaxima S.A. is the only producer of MIC tests in Central Europe and one of the few such manufacturers worldwide. We are pleased that a product based on our experience and technologies can serve as the foundation for the production of such a specialized product."
BioMaxima S.A. is a Polish company operating in the laboratory diagnostics market, listed on the main market of the Warsaw Stock Exchange (WSE). The company specializes in the production of systems for the diagnosis of infectious diseases, including microbiological tests, antimicrobial susceptibility testing systems, and a wide range of reagents and equipment for in vitro diagnostics. The company is also a distributor of products from globally recognized diagnostic firms such as Biolog Inc., Accelerate Diagnostics, Inc., and Nova Biomedical. The company supplies its products to over 2,000 laboratories in Poland and exports to more than 60 markets.
Media contact:
media@biomaxima.com
www.biomaxima.com